The Iran war is providing an unexpected boost to secondary city travel in Asia-Pacific
Trips to smaller “secondary cities” in Asia-Pacific are getting an added boost this summer, as the Iran war is spurring travelers to plan trips closer to home.
CNBC Daily Open: The ‘outwaiting’ game hampers Iran peace talks
Conflicting accounts of the status of peace talks between the U.S. and Iran create a confusing market picture at the end of the trading week.
CNBC Daily Open: The ‘outwaiting’ game hampers Iran peace talks
Conflicting accounts of the status of peace talks between the U.S. and Iran create a confusing market picture at the end of the trading week.
Strait of Hormuz shutdown: A visual guide to world’s most critical oil chokepoint
Data shows how the outbreak of the Iran war in February and the closure of the Strait of Hormuz saw trade grind to a halt, triggering a severe global energy shock.
Strait of Hormuz shutdown: A visual guide to world’s most critical oil chokepoint
Data shows how the outbreak of the Iran war in February and the closure of the Strait of Hormuz saw trade grind to a halt, triggering a severe global energy shock.
I was at the exclusive launch of Ferrari’s new EV that sent the stock tumbling. But there may be light at the end of the tunnel
Is there a “luce” at the end of the tunnel for Ferrari’s first electric vehicle?
Nvidia is investing billions into this emerging technology that could change the AI industry
Photonics is considered to be a more efficient alternative to the current process of transferring data using electricity, which could be crucial to the AI boom.
The ECB is in a bind over rate hikes — the private sector could be doing the bank’s job for it
Market expectations that the European Central Bank will hike interest rates this year have already contributed to tighter financial and lending conditions.
Blue Origin warns of rocket explosion debris after failed New Glenn test at Cape Canaveral
Jeff Bezos’ rocket maker suffered a setback on Thursday as its New Glenn rocket went up in flames.
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.
